Anti-tumor efficacy of lidamycin in combination with chemotherapeutic drugs
SHANG Bo-yang
WU Shu-ying
SHANG Yue
LI Dian-dong
ZHEN Yong-su
Abstract：Objective: To investigate the synergistic anti-tumor effect of lidamycin (LDM) in combination with several clinical anti-tumor drugs including 5-fluorouracil (5Fu) , paclitaxel (TAX) , adriamycin (ADM) , na-velbine (NVB) and cisplatin (CDDP) in vitro and in vivo. Methods: Cytotoxicity of drug combination toward various human tumor cell lines was determined by clonogenic assay in vitro. Tumor inhibitory effect in vivo was evaluated by using the model of subcutaneously transplanted hepatoma 22 in KM mice. The coefficient of drug interaction (CDI) was used to analyze the synergistic effect of drug combination. Results: LDM in combination with 5-Fu, NVB, TAX, ADM, or CDDP showed a significant synergistic anti-tumor effect in vitro as the CDI for each combination was less than 0. 7. In the model of subcutaneously transplanted hepatoma 22 in vivo, LDM in combination with 5-Fu, TAX, and NVB/CDDP effectively inhibited the growth of H22 in mice; the optimum CDI for each combination was 0. 92, 0. 89, and 0.96, respectively. Conclusion: Lidamycin shows a synergetic anti-tumor effect in combination respectively with several anti-tumor drugs in vitro and in vivo, which implies a clinical prospect of this combination treatment.
Keywords：anti-tumorenediynelidamycinsynergetic effect
Publication Date：2009-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：6( 2075-2080 )